Table 4.
Clinical and pathology characteristics of patients with endometrioid endometrial cancer, stratified by TP53.
| Characteristic |
TP53 Wildtype (n = 213) |
TP53 Mutant (n = 32) |
p-value |
|---|---|---|---|
|
| |||
| Age in years, mean (SD) | 59.2 (11.4) | 59.1 (13.7) | 0.98 |
|
| |||
| Body mass index in kg/m2, mean (SD)a | 34.9 (10.5) | 35.8 (12.3) | 0.99 |
|
| |||
| Race, n (%) | > 0.99 | ||
| White | 150 (70%) | 23 (75%) | |
| Black | 11 (5%) | 1 (3%) | |
| Hispanic | 41 (19%) | 6 (19%) | |
| Asian | 10 (5%) | 1 (3%) | |
| Other | 1 (0%) | 0 (0%) | |
|
| |||
| Grade, n (%)b | < 0.001 | ||
| 1 | 27 (13%) | 3 (9%) | |
| 2 | 148 (71%) | 13 (41%) | |
| 3 | 32 (15%) | 16 (50%) | |
|
| |||
| Myometrial invasion, n (%)c | 0.51 | ||
| < 50% | 124 (61%) | 17 (55%) | |
| ≥ 50% | 79 (39%) | 14 (45%) | |
|
| |||
| Lymphovascular space invasion, n (%)d | 0.16 | ||
| No | 104 (52%) | 12 (39%) | |
| Yes | 95 (48%) | 19 (61%) | |
|
| |||
| Tumor size in cm, mean (SD)e | 4.4 (2.9) | 5.1 (4.4) | 0.89 |
|
| |||
| Stage, n (%)f | 0.59 | ||
| I or II | 152 (72%) | 21 (68%) | |
| III or IV | 58 (28%) | 10 (32%) | |
|
| |||
| Mutations | |||
| KRAS | 46 (22%) | 6 (19%) | 0.71 |
| PIK3CA | 87 (41%) | 14 (44%) | 0.76 |
| CTNNB1 | 51 (24%) | 2 (6%) | 0.02 |
| PTEN | 120 (56%) | 12 (38%) | < 0.05 |
| FGFR2 | 23 (11%) | 5 (16%) | 0.42 |
| ARID1Ag | 64 (44%) | 4 (27%) | 0.28 |
| PIK3R1g | 38 (26%) | 5 (33%) | 0.53 |
243 patients were included in BMI assessment for the endometrioid cohort; 2 patients did not have either a height or weight recorded at the time of their initial evaluation at the University of Texas MD Anderson Cancer Center.
239 patients were included in the grade assessment for the endometrioid cohort; 6 received neoadjuvant chemotherapy.
317 and 234 patients were included in the myometrial invasion assessment for the endometrioid cohort; 6 received neoadjuvant, 5 did not have invasion information available.
230 patients were included in the LVSI assessment for the endometrioid cohort; 6 received neoadjuvant chemotherapy, 9 patients did not have LVSI information available.
222 patients were included in the tumor size assessment for the endometrioid cohort; 6 received neoadjuvant chemotherapy, 17 did not have accurate tumor size information available.
241 patients were included in the stage assessment for the endometrioid cohort; 4 patients did not have clinical, pathology, or radiological information available for stage assessment.
162 patients were included in the analyses for the endometrioid cohort for both ARID1A and PIK3R1.